Pharmacological pig study stopped

Pharmacological pig study stopped During preparations for the pharmacological study of GPG® and its active metabolite on pigs, certain problems have been observed with the breakdown of the metabolite. When validating the analytical method used for the metabolite, it has been found that the blood of pigs in the test specifically, breaks down the metabolite. This was a highly unexpected finding, since the metabolite is not broken down in human blood. It can be noted that it is the metabolite that is responsible for GPG®'s positive antiviral effect in vitro. As previously announced, the patent for the metabolite is now pending. With what the company now knows, a pharmacological study on pigs is no longer considered to be justified. For further information, please contact: Hans Möller, President and CEO, tel. +46-8-449 84 80, mobile: +46-708-15 16 89, e-mail: hans.moller@tripep.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2002/05/28/20020528BIT01180/wkr0001.doc http://www.waymaker.net/bitonline/2002/05/28/20020528BIT01180/wkr0002.pdf